Your browser doesn't support javascript.
loading
Estrogen-Wnt signaling cascade regulates expression of hepatic fibroblast growth factor 21.
Badakhshi, Yasaman; Shao, Weijuan; Liu, Dinghui; Tian, Lili; Pang, Juan; Gu, Jianqiu; Hu, Jim; Jin, Tianru.
Affiliation
  • Badakhshi Y; Department of Physiology, Faculty of Medicine, University of Toronto, Toronto, Canada.
  • Shao W; Divison of Advanced Diagnostics, Toronto General Hospital Research Institute, University Health Network, Toronto, Canada.
  • Liu D; Banting and Best Diabetes Centre, Faculty of Medicine, University of Toronto, Toronto, Canada.
  • Tian L; Department of Physiology, Faculty of Medicine, University of Toronto, Toronto, Canada.
  • Pang J; Divison of Advanced Diagnostics, Toronto General Hospital Research Institute, University Health Network, Toronto, Canada.
  • Gu J; Banting and Best Diabetes Centre, Faculty of Medicine, University of Toronto, Toronto, Canada.
  • Hu J; Department of Physiology, Faculty of Medicine, University of Toronto, Toronto, Canada.
  • Jin T; Department of Cardiology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, People's Republic of China.
Am J Physiol Endocrinol Metab ; 321(2): E292-E304, 2021 08 01.
Article in En | MEDLINE | ID: mdl-34229476
We have generated the transgenic mouse line LTCFDN in which dominant negative TCF7L2 (TCF7L2DN) is specifically expressed in the liver during adulthood. Male but not female LTCFDN mice showed elevated hepatic and plasma triglyceride (TG) levels, indicating the existence of estrogen-ß-cat/TCF signaling cascade that regulates hepatic lipid homeostasis. We show here that hepatic fibroblast growth factor 21 (FGF21) expression was reduced in male but not in female LTCFDN mice. The reduction was not associated with altered hepatic expression of peroxisome proliferator-activated receptor α (PPARα). In mouse primary hepatocytes (MPH), Wnt-3a treatment increased FGF21 expression in the presence of PPARα inhibitor. Results from our luciferase-reporter assay and chromatin immunoprecipitation suggest that evolutionarily conserved TCF binding motifs (TCFBs) on Fgf21 promoter mediate Wnt-3a-induced Fgf21 transactivation. Female mice showed reduced hepatic FGF21 production and circulating FGF21 level following ovariectomy (OVX), associated with reduced hepatic TCF expression and ß-catenin S675 phosphorylation. Finally, in MPH, estradiol (E2) treatment enhanced FGF21 expression, as well as binding of TCF7L2 and ribonucleic acid (RNA) polymerase II to the Fgf21 promoter; and the enhancement can be attenuated by the G-protein-coupled estrogen receptor 1 (GPER) antagonist G15. Our observations hence indicate that hepatic FGF21 is among the effectors of the newly recognized E2-ß-cat/TCF signaling cascade.NEW & NOTEWORTHY FGF21 is mainly produced in the liver. Therapeutic effect of FGF21 analogues has been demonstrated in clinical trials on reducing hyperlipidemia. We show here that Fgf21 transcription is positively regulated by Wnt pathway effector ß-cat/TCF. Importantly, hepatic ß-cat/TCF activity can be regulated by the female hormone estradiol, involving GPER. The investigation enriched our understanding on hepatic FGF21 hormone production, and expanded our view on metabolic functions of the Wnt pathway in the liver.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Wnt Signaling Pathway / Fibroblast Growth Factors / Liver Limits: Animals Language: En Journal: Am J Physiol Endocrinol Metab Journal subject: ENDOCRINOLOGIA / FISIOLOGIA / METABOLISMO Year: 2021 Document type: Article Affiliation country: Country of publication:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Wnt Signaling Pathway / Fibroblast Growth Factors / Liver Limits: Animals Language: En Journal: Am J Physiol Endocrinol Metab Journal subject: ENDOCRINOLOGIA / FISIOLOGIA / METABOLISMO Year: 2021 Document type: Article Affiliation country: Country of publication: